Andhra Pradesh-based manufacturer of bulk pharmaceutical ingredients (APIs), operating under a related-party manufacturing arrangement with promoter Ipca Laboratories.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 18 | 20 | 22 | 22 | 22 | 22 | 22 | 22 |
| Reserves | -43 | -62 | -97 | -121 | -141 | -168 | -179 | -184 |
| Borrowings | 66 | 111 | 143 | 183 | 194 | 212 | 219 | 225 |
| Other Liabilities | 93 | 91 | 122 | 91 | 104 | 103 | 106 | 101 |
| Total Liabilities | 134 | 159 | 190 | 175 | 178 | 169 | 168 | 163 |
| AssetsFixed Assets | 105 | 118 | 139 | 147 | 150 | 146 | 146 | 142 |
| CWIP | 4 | 12 | 8 | 4 | 2 | 3 | 1 | 2 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 24 | 29 | 43 | 24 | 26 | 20 | 20 | 20 |
| Total Assets | 134 | 159 | 190 | 175 | 178 | 169 | 168 | 163 |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 4 | -36 | -15 | -17 | -25 | 2 | -8 | -2 |
| Cash from Investing | -4 | -10 | -23 | -23 | -13 | -8 | -5 | -4 |
| Cash from Financing | 17 | 29 | 38 | 40 | 37 | 6 | 13 | 6 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | -1 | -45 | -40 | -41 | -36 | -5 | -11 | -5 |
| FCF Margin | — | — | — | — | — | — | — | — |
For capital-heavy businesses (telecom, power, heavy manufacturing) reported profit ignores the cash needed just to stand still. We'd systematically overvalue it, so we don't show a number.
KREBSBIO · CAPITAL_INTENSIVE
Guides on how to read this kind of business and the numbers that matter.